Immunogen said in a release that its financial guidance for 2011 is no longer valid.

FORBES: Bad News For Immunogen

ImmunoGen said T-DM1 is the most advanced drug candidate that uses its technology.

WSJ: Roche Breast-Cancer Treatment Advances

The two other components of T-DM1, both developed by ImmunoGen Inc.

WSJ: Roche Breast-Cancer Treatment Advances

Immunogen suffered a big setback in August when the FDA refused to even consider approving the new T-DM1 breast cancer drug its partner Roche is testing based on its technology.

FORBES: Novartis Deal Bolsters Immunogen

This morning, Roche announced that the Food and Drug Administration refused to consider the application for the TDM-1 breast cancer drug based on technology that it licensed from Immunogen, a Waltham, Mass. biotechnology company.

FORBES: Bad News For Immunogen

Genentech licenses technology used in Kadcyla from Immunogen.

FORBES: A Triumph In Breast Cancer -- And Another Expensive Drug

Some researchers, including Nancy Kedersha, a biologist at ImmunoGen (a biotechnology company in Cambridge, Massachusetts) who was one of the discoverers of vaults, think they regularly switch from open (ie, flowers) to closed (ie, barrels).

ECONOMIST: Cell biology: The secret of the vaults | The

Immunogen also has a deal with SanofiAventis.

FORBES: Novartis Deal Bolsters Immunogen